Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3049% above fair value
$68.53−0.78 (-1.13%)
Close on Nov 16, 2026Market cap $39.40BP/E 38.9Yield –
Royalty Pharma cash
Cash and short-term investments held at the end of each period.
Royalty Pharma's cash was $836.99M at Jun 30, 2026. For fiscal 2025 it was $637.50M, down 35.4% from the year before. The highest annual figure on record is $1.92B in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $637.50M | -35.4% |
| FY2024 | Dec 31, 2024 | $987.23M | +99.3% |
| FY2023 | Dec 31, 2023 | $495.31M | -71.1% |
| FY2022 | Dec 31, 2022 | $1.71B | +6.5% |
| FY2021 | Dec 31, 2021 | $1.61B | +49.0% |
| FY2020 | Dec 31, 2020 | $1.08B | +338.1% |
| FY2019 | Dec 31, 2019 | $246.20M | -87.2% |
| FY2018 | Dec 31, 2018 | $1.92B | +39.3% |
| FY2017 | Dec 31, 2017 | $1.38B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $836.99M | +29.7% |
| Q1 FY2026 | Mar 31, 2026 | $608.30M | -44.7% |
| Q4 FY2025 | Dec 31, 2025 | $637.50M | -35.4% |
| Q3 FY2025 | Sep 30, 2025 | $955.04M | -4.4% |
| Q2 FY2025 | Jun 30, 2025 | $645.11M | -64.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.10B | +26.1% |
| Q4 FY2024 | Dec 31, 2024 | $987.23M | +99.3% |
| Q3 FY2024 | Sep 30, 2024 | $998.55M | +6.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.80B | -17.2% |
| Q1 FY2024 | Mar 31, 2024 | $872.00M | -55.9% |
| Q4 FY2023 | Dec 31, 2023 | $495.31M | -71.1% |
| Q3 FY2023 | Sep 30, 2023 | $941.75M | -32.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.18B | -11.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.98B | +6.6% |
| Q4 FY2022 | Dec 31, 2022 | $1.71B | +6.5% |
| Q3 FY2022 | Sep 30, 2022 | $1.40B | -25.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.47B | +104.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.86B | +138.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.61B | +49.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.87B | +17.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.21B | -48.5% |
| Q1 FY2021 | Mar 31, 2021 | $778.07M | +56.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.08B | +338.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.60B | +1271.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.35B | +296.1% |
| Q1 FY2020 | Mar 31, 2020 | $498.07M | -74.1% |
| Q4 FY2019 | Dec 31, 2019 | $246.20M | -82.2% |
| Q3 FY2019 | Sep 30, 2019 | $116.39M | – |
| Q2 FY2019 | Jun 30, 2019 | $593.32M | – |
| Q4 FY2018 | Dec 31, 2018 | $1.92B | – |
| Q4 FY2017 | Dec 31, 2017 | $1.38B | – |
See a number that looks wrong?